View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 16, 2021

Coronavirus company news summary – FDA authorises Qorvo Biotechnologies’ rapid Covid-19 antigen test – JOYSBIO Covid-19 neutralising antibody rapid test 98% accurate

By Chloe Kent

Qorvo Biotechnologies has announced that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to its Qorvo Omnia SARS-CoV-2 antigen test. The test is now approved to detect viral antigens from SARS-CoV-2 in nasal swabs of suspected individuals.

A clinical study carried out in Italy has found the JOYSBIO Covid-19 neutralising antibody rapid test kit to be 98.05% effective in verifying neutralising antibodies after subjects got vaccinated with the Pfizer-BioNTech vaccine. The inexpensive kit delivers results in 25 to 30 minutes, and could be used to analyse people’s immunity status.

Seegene has announced that its Italian subsidiary, Arrow Diagnostics, has secured the public procurement worth over $99.04m, the largest volume of tender for its Italian branch. As per the agreement, Arrow Diagnostics is expected to supply about 7.15 million Covid-19 diagnostic tests along with extraction reagents to the Italian Ministry of Defence. The Covid-19 diagnostic tests will be distributed across 17 regions including Liguria, Lombardy, Tuscany, and Veneto.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU